Holen Sie sich die Stockscreener-App
2.66
1.12%
-0.03
Handel nachbörslich:
2.66
Schlusskurs vom Vortag:
$2.69
Offen:
$2.72
24-Stunden-Volumen:
565.39K
Relative Volume:
1.02
Marktkapitalisierung:
$195.87M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
53.20
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
+9.47%
1M Leistung:
+18.75%
6M Leistung:
+166.00%
1J Leistung:
+79.73%
1-Tages-Spanne:
$2.615
$2.72
1-Wochen-Bereich:
$2.325
$2.76
52-Wochen-Spanne:
$0.8214
$2.76
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Vergleichen Sie PLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.66 | 195.87M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Protalix BioTherapeutics (NYSE:PLX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Insider’s View: Deciphering Protalix BioTherapeutics Inc (PLX)’s Financial Health Through Ratios - The Dwinnex
Was Protalix BioTherapeutics Inc (PLX)’s session last reading good? - US Post News
Research Analysts Set Expectations for PLX FY2025 Earnings - Defense World
What is HC Wainwright’s Forecast for PLX FY2024 Earnings? - Defense World
Zacks Small Cap Has Negative Outlook for PLX FY2025 Earnings - MarketBeat
What is HC Wainwright's Estimate for PLX FY2024 Earnings? - MarketBeat
H.C. Wainwright lifts Protalix stock target to $15, maintains buy - MSN
Research Analysts Issue Forecasts for PLX Q1 Earnings - Defense World
Protalix Biotherapeutics gains momentum in the rare disease space: analysts - Proactive Investors USA
Perhaps timely catching Protalix BioTherapeutics Inc (PLX) would be a good idea - SETE News
What is HC Wainwright's Forecast for PLX Q1 Earnings? - MarketBeat
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - WV News
Protalix BioTherapeutics (NYSE:PLX) Given New $15.00 Price Target at HC Wainwright - Defense World
Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World
PLX: Revisiting the Thesis - Research Tree
Will Protalix remain independent? - גלובס
Protalix BioTherapeutics (NYSE:PLX) Rating Lowered to Buy at StockNews.com - Defense World
Protalix BioTherapeutics (NYSE:PLX) Lowered to "Buy" Rating by StockNews.com - MarketBeat
Protalix BioTherapeutics Outlines Strategic Roadmap for 2025 - Proactive financial news
Jane Street Group LLC Has $47,000 Position in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
Hypophosphatasia Treatment Market reached US$ 841.9 million - openPR
US Penny Stocks: Arbe Robotics And 2 More Promising Picks - Simply Wall St
Who's Going to Buy This Orphan Drugmaker? - AOL
PLX stock touches 52-week high at $2.17 amid robust gains - Investing.com
Head-To-Head Analysis: Humacyte (NASDAQ:HUMA) & Protalix BioTherapeutics (NYSE:PLX) - Defense World
Sanctuary Advisors LLC Acquires New Shares in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
MB Sounding Board: Dual Listed Companies and Associated Challenges - Mayer Brown
Protalix Achieves Key Milestones and Remains Debt-Free - TipRanks
Protalix BioTherapeutics Hits Key Milestones: Debt-Free Status, Revenue Growth & Clinical Progress - StockTitan
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
Protalix BioTherapeutics' Phase 1 Data Bolsters Gout Aspirations (Rating Upgrade) - Seeking Alpha
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Less frequent Elfabrio ERT regimen for Fabry up for EU approval –... - Fabry Disease News
EMA validates Chiesi and Protalix’s dose variation for Fabry disease - Yahoo Finance
EMA validates Chiesi/Protalix’s submission of pegunigalsidase alfa - Pharmaceutical Technology
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa – Company AnnouncementFT.com - Financial Times
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa - PR Newswire
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 - The Eastern Progress Online
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results - The Eastern Progress Online
Botanical and Plant-Derived Drugs Market to grow by USD 20.93 Billion (2024-2028), driven by government initiatives, with AI powering market evolutionTechnavio - Yahoo Finance
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease - Yahoo Finance
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Inc. (PLX) Quarterly 10-Q Report - Quartzy
Protalix: Q3 Earnings Snapshot - New Haven Register
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Protalix BioTherapeutics Reports Strong Q3 2024 Results - TipRanks
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results - citybiz
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 - The Malaysian Reserve
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):